Evaluating the Safety and Immune Response of DNA/MVA Vaccines in HIV-1-Infected Young Adults Taking Anti-HIV Medications

Inclusion Criteria: * HIV-1 infected. More details on this criterion can be found in the protocol. * Likely HIV-1 acquisition in North America or Europe (in the opinion of the site investigator) * Likely HIV-1 acquisition from sexual transmission (in the opinion of the site investigator) * On stable HAART, defined as at least three different antiretrovirals (ARVs) from two different classes, with plasma HIV-1 RNA levels fewer than 100 copies/mL for at least 12 months prior to screening. Furthermore, at least two plasma HIV-1 RNA levels fewer than 100 copies/mL (and none with plasma HIV-1 RNA levels 100 or more copies/mL), separated by at least 3 months must have been documented during the 6-month period prior to enrollment. * Ability and willingness of participant to provide signed written informed consent * CD4 count 400 cells/mm\^3 or greater at screening * The following lab values (at screening visit): * Creatine phosphokinase no higher than 5 times the upper limit of normal (ULN). More details on this criterion can be found in the protocol. * Troponin I no more than 1.0 times ULN * Hemoglobin greater than 10 g/dL * Absolute neutrophil count greater than 1,000 mm\^3 * Platelets greater than 100,000 mm\^3 * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) no greater than 1.5 times ULN * Total bilirubin no greater than 1.5 times ULN (less than 5 times ULN if taking atazanavir) * Creatinine less than 2.0 mg/dL * Female participants who eng…